Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 12/2010

Open Access 01-12-2010 | Original paper

Toenail selenium status and the risk of Barrett’s esophagus: the Netherlands Cohort Study

Authors: Jessie Steevens, Leo J. Schouten, Ann L. C. Driessen, Clément J. R. Huysentruyt, Yolande C. A. Keulemans, R. Alexandra Goldbohm, Piet A. van den Brandt

Published in: Cancer Causes & Control | Issue 12/2010

Login to get access

Abstract

Objective

To investigate the association between selenium and the risk of Barrett’s esophagus (BE), the precursor lesion of esophageal adenocarcinoma.

Methods

Data from the prospective Netherlands Cohort Study were used. This cohort study was initiated in 1986, when 120,852 subjects aged 55–69 years completed a questionnaire on dietary habits and lifestyle, and provided toenail clippings for the determination of baseline selenium status. After 16.3 years of follow-up, 253 BE cases (identified through linkage with the nationwide Dutch pathology registry) and 2,039 subcohort members were available for case–cohort analysis. Cox proportional hazards models were used to calculate incidence rate ratios (RR).

Results

The multivariable-adjusted RR for the highest versus the lowest quartile of toenail selenium was 1.06 (95% CI 0.71–1.57). No dose–response trend was seen (p trend = 0.99). No association was found in subgroups defined by sex, smoking status, body mass index (BMI), or intake of antioxidants. For BE cases that later progressed to high-grade dysplasia or adenocarcinoma, the RR for a selenium level above the median vs. below the median was 0.64 (95% CI 0.24–1.76).

Conclusions

In this large prospective cohort study, we found no evidence of an association between selenium and risk of BE.
Appendix
Available only for authorised users
Literature
1.
Wang KK, Sampliner RE (2008) Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol 103:788–797CrossRefPubMed
2.
Playford RJ (2006) New British society of gastroenterology (Bsg) guidelines for the diagnosis and management of Barrett’s oesophagus. Gut 55:442–443CrossRefPubMed
3.
4.
Post PN, Siersema PD, van Dekken H (2007) Rising incidence of clinically evident Barrett’s oesophagus in the Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol 42:17–22CrossRefPubMed
5.
Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L (2008) The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis. Am J Epidemiol 168:237–249CrossRefPubMed
6.
Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P (2008) Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 67:394–398CrossRefPubMed
7.
Wild CP, Hardie LJ (2003) Reflux, Barrett’s oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 3:676–684CrossRefPubMed
8.
Anderson LA, Watson RG, Murphy SJ et al (2007) Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 13:1585–1594PubMed
9.
Kubo A, Levin TR, Block G et al (2008) Dietary patterns and the risk of Barrett’s esophagus. Am J Epidemiol 167:839–846CrossRefPubMed
10.
Navarro Silvera SA, Rohan TE (2007) Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control 18:7–27CrossRefPubMed
11.
World Cancer Research Fund, American Institute for Cancer Research (2007) Food, nutrition, physical activity and the prevention of cancer: a global perspective. AICR, Washington, DC
12.
Clark LC, Combs GF Jr, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group. JAMA 276:1957–1963CrossRefPubMed
13.
Rayman MP (2005) Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 64:527–542CrossRefPubMed
14.
Steevens J, van den Brandt PA, Goldbohm RA, Schouten LJ (2010) Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology 138:1704–1713CrossRefPubMed
15.
Rudolph RE, Vaughan TL, Kristal AR et al (2003) Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett’s esophagus. J Natl Cancer Inst 95:750–757CrossRefPubMed
16.
Moe GL, Kristal AR, Levine DS, Vaughan TL, Reid BJ (2000) Waist-to-hip ratio, weight gain, and dietary and serum selenium are associated with DNA content flow cytometry in Barrett’s esophagus. Nutr Cancer 36:7–13CrossRefPubMed
17.
Peng DF, Razvi M, Chen H et al (2009) DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett’s adenocarcinoma. Gut 58:5–15CrossRefPubMed
18.
Willett WC, Buzzard IM (1998) Foods and nutrients. In: Willett WC (ed) Monographs in epidemiology and biostatistics volume 30 nutritional epidemiology. Oxford University Press, New York, pp 18–32
19.
Longnecker MP, Stram DO, Taylor PR et al (1996) Use of selenium concentration in whole blood, serum, toenails, or urine as a surrogate measure of selenium intake. Epidemiology 7:384–390CrossRefPubMed
20.
Hunter DJ, Morris JS, Chute CG et al (1990) Predictors of selenium concentration in human toenails. Am J Epidemiol 132:114–122PubMed
21.
van den Brandt PA, Goldbohm RA, van ‘t Veer P, Volovics A, Hermus RJ, Sturmans F (1990) A large-scale prospective cohort study on diet and cancer in the Netherlands. J Clin Epidemiol 43:285–295CrossRefPubMed
22.
Barlow WE, Ichikawa L, Rosner D, Izumi S (1999) Analysis of case-cohort designs. J Clin Epidemiol 52:1165–1172CrossRefPubMed
23.
Casparie M, Tiebosch AT, Burger G et al (2007) Pathology data banking and bio banking in the Netherlands, a central role for plage, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19–24PubMed
24.
van den Brandt PA, Schouten LJ, Goldbohm RA, Dorant E, Hunen PM (1990) Development of a record linkage protocol for use in the Dutch cancer registry for epidemiological research. Int J Epidemiol 19:553–558CrossRefPubMed
25.
Zeegers MP, Goldbohm RA, Bode P, van den Brandt PA (2002) Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 11:1292–1297PubMed
26.
Bode P (2000) Automation and quality assurance in the neutron activation facilities in delft. J Radioanal Nucl Chem 245:127–132CrossRef
27.
van den Brandt PA, Goldbohm RA, van’t Veer P, Bode P, Hermus RJ, Sturmans F (1993) Predictors of toenail selenium levels in men and women. Cancer Epidemiol Biomarkers Prev 2:107–112PubMed
28.
van den Brandt PA, Goldbohm RA, van ‘t Veer P et al (1993) A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. J Natl Cancer Inst 85:224–229CrossRefPubMed
29.
van Breda SG, Hogervorst JG, Schouten LJ et al (2007) Toenails: an easily accessible and long-term stable source of DNA for genetic analyses in large-scale epidemiological studies. Clin Chem 53:1168–1170CrossRefPubMed
30.
Anonymous (1986) Nevo table: Dutch food composition table, 1986–1987. (Dutch). The Hague, Netherlands: Voorlichtingbureau Voor de Voeding
31.
Goldbohm RA, van den Brandt PA, Brants HA et al (1994) Validation of a dietary questionnaire used in a large-scale prospective cohort study on diet and cancer. Eur J Clin Nutr 48:253–265PubMed
32.
Lagergren J, Bergstrom R, Adami HO, Nyren O (2000) Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 133:165–175PubMed
33.
Cox DR (1972) Regression models and life-tables. J Roy Statistical Society 34:187–220
34.
35.
Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239–241CrossRef
36.
Gao S, Jin Y, Hall KS et al (2007) Selenium level and cognitive function in rural elderly Chinese. Am J Epidemiol 165:955–965CrossRefPubMed
37.
Ovaskainen ML, Virtamo J, Alfthan G et al (1993) Toenail selenium as an indicator of selenium intake among middle-aged men in an area with low soil selenium. Am J Clin Nutr 57:662–665PubMed
38.
Garland M, Morris JS, Rosner BA et al (1993) Toenail trace element levels as biomarkers: reproducibility over a 6 year period. Cancer Epidemiol Biomarkers Prev 2:493–497PubMed
39.
Koriyama C, Campos FI, Yamamoto M et al (2008) Toenail selenium levels and gastric cancer risk in Cali, Colombia. J Toxicol Sci 33:227–235CrossRefPubMed
40.
Cai J, Zeng D (2004) Sample size/power calculation for case-cohort studies. Biometrics 60:1015–1024CrossRefPubMed
41.
Fan X, Snyder N (2009) Prevalence of Barrett’s esophagus in patients with or without gerd symptoms: role of race, age, and gender. Dig Dis Sci 54:572–577CrossRefPubMed
42.
Gerson LB, Shetler K, Triadafilopoulos G (2002) Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology 123:461–467CrossRefPubMed
43.
Ward EM, Wolfsen HC, Achem SR et al (2006) Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 101:12–17CrossRefPubMed
44.
Rothman KJ, Greenland S (1998) Precision and validity in epidemiologic studies. In: Rothman KJ, Greenland S (eds) Modern epidemiology, 2nd edn. Lippincott, Philadelphia, pp 115–134
Metadata
Title
Toenail selenium status and the risk of Barrett’s esophagus: the Netherlands Cohort Study
Authors
Jessie Steevens
Leo J. Schouten
Ann L. C. Driessen
Clément J. R. Huysentruyt
Yolande C. A. Keulemans
R. Alexandra Goldbohm
Piet A. van den Brandt
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 12/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9651-1

Other articles of this Issue 12/2010

Cancer Causes & Control 12/2010 Go to the issue

Original paper

The aetiology of upper aerodigestive tract cancers among young adults in Europe: the ARCAGE study

Original paper

Glycemic index, glycemic load, and the risk of pancreatic cancer among postmenopausal women in the women’s health initiative observational study and clinical trial

Original paper

Light at night and breast cancer risk: results from a population-based case–control study in Connecticut, USA

Original paper

Dietary acrylamide intake and the risk of cancer among Finnish male smokers

Original paper

Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case–control study

Original paper

Research and comprehensive cancer control coalitions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits